Correlation Between Mereo BioPharma and UBS Plc

Can any of the company-specific risk be diversified away by investing in both Mereo BioPharma and UBS Plc at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mereo BioPharma and UBS Plc into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mereo BioPharma Group and UBS plc , you can compare the effects of market volatilities on Mereo BioPharma and UBS Plc and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mereo BioPharma with a short position of UBS Plc. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mereo BioPharma and UBS Plc.

Diversification Opportunities for Mereo BioPharma and UBS Plc

-0.69

Correlation Coefficient

Mereo BioPharma  UBS Plc

Excellent diversification

The 3 months correlation between Mereo and UBS is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding Mereo BioPharma Group and UBS plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UBS plc and Mereo BioPharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mereo BioPharma Group are associated (or correlated) with UBS Plc. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UBS plc has no effect on the direction of Mereo BioPharma i.e., Mereo BioPharma and UBS Plc go up and down completely randomly.

Pair Corralation between Mereo BioPharma and UBS Plc

Assuming the 90 days trading horizon Mereo BioPharma is expected to generate 1.07 times less return on investment than UBS Plc. In addition to that, Mereo BioPharma is 5.48 times more volatile than UBS plc . It trades about 0.02 of its total potential returns per unit of risk. UBS plc is currently generating about 0.14 per unit of volatility. If you would invest  823,419  in UBS plc on September 5, 2024 and sell it today you would earn a total of  104,281  from holding UBS plc or generate 12.66% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	99.22%
Values	Daily Returns

Mereo BioPharma Group  vs.  UBS plc

Mereo BioPharma Group

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mereo BioPharma Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

UBS plc

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in UBS plc are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, UBS Plc may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Mereo BioPharma and UBS Plc

The main advantage of trading using opposite Mereo BioPharma and UBS Plc positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mereo BioPharma position performs unexpectedly, UBS Plc can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UBS Plc will offset losses from the drop in UBS Plc's long position.

The idea behind Mereo BioPharma Group and UBS plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.